BioXcel Therapeutics (BTAI) Research & Development (2022 - 2025)
Historic Research & Development for BioXcel Therapeutics (BTAI) over the last 4 years, with Q3 2025 value amounting to $8.7 million.
- BioXcel Therapeutics' Research & Development rose 7133.9% to $8.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.5 million, marking a year-over-year decrease of 1455.55%. This contributed to the annual value of $30.4 million for FY2024, which is 6390.79% down from last year.
- Per BioXcel Therapeutics' latest filing, its Research & Development stood at $8.7 million for Q3 2025, which was up 7133.9% from $10.3 million recorded in Q2 2025.
- Over the past 5 years, BioXcel Therapeutics' Research & Development peaked at $32.5 million during Q4 2022, and registered a low of $4.6 million during Q1 2025.
- Moreover, its 4-year median value for Research & Development was $11.4 million (2024), whereas its average is $15.3 million.
- As far as peak fluctuations go, BioXcel Therapeutics' Research & Development crashed by 7399.97% in 2024, and later surged by 7133.9% in 2025.
- BioXcel Therapeutics' Research & Development (Quarter) stood at $32.5 million in 2022, then crashed by 69.4% to $9.9 million in 2023, then plummeted by 40.6% to $5.9 million in 2024, then surged by 48.11% to $8.7 million in 2025.
- Its last three reported values are $8.7 million in Q3 2025, $10.3 million for Q2 2025, and $4.6 million during Q1 2025.